Envelope icon

Subscribe to our newsletter

Get regular updates to your inbox.

Single Dose of Gene Therapy AMT-061 Proves Effective in Hemophilia B

A single administration of AMT-061, an investigational gene therapy for people with severe and moderately severe hemophilia B, increased therapeutic levels of factor IX (FIX) in all patients enrolled in uniQure’s ongoing Phase 2b trial, the company announced. Ultimately, this trial's purpose is...